# EDGAR Filing Document

**Accession Number:** 0001885827
**File Stem:** 0001193125-25-335379
**Filing Date:** 2025-12
**Character Count:** 1976
**Document Hash:** 3afe06dca1be84926f51182591abe111
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-335379.hdr.sgml**: 20260421

**ACCESSION NUMBER**: 0001193125-25-335379

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251229

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Virax Biolabs Group Ltd
- **CENTRAL INDEX KEY:** 0001885827
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** BIOCITY GLASGOW
- **STREET 2:** BO'NESS ROAD, NEWHOUSE
- **CITY:** LANARKSHIRE
- **STATE:** X0
- **ZIP:** ML1 5UH
- **BUSINESS PHONE:** 44 020 7788 7414

**MAIL ADDRESS:**
- **STREET 1:** BIOCITY GLASGOW
- **STREET 2:** BO'NESS ROAD, NEWHOUSE
- **CITY:** LANARKSHIRE
- **STATE:** X0
- **ZIP:** ML1 5UH

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Virax Biolabs (Cayman) Ltd
- **DATE OF NAME CHANGE:** 20210930

**Virax Biolabs Group Limited**

**BioCity Glasgow**

**Bo'Ness Road Newhouse**

**Lanarkshire, ML1 SUH**

**United Kingdom**

**<u>VIA EDGAR</u>**

December 29, 2025

U.S. Securities & Exchange Commission

Office of Life Sciences

Division of Corporation Finance

100 F Street, NE

Attn: Jessica Dickerson

---

| | |
|:---|:---|
| **Re:** | **Virax Biolabs Group Limited** |
|  | **Registration Statement on Form F-3** |
|  | **Filed December 18, 2025** |
|  | **File No. 333-292241** |

---

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Virax Biolabs Group Limited hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:00 p.m., Eastern Time, on December 30, 2025, or as soon as thereafter practicable.

---

| |
|:---|
| Very truly yours, |
| */s/ James Foster* |
| James Foster<br>Chief Executive Officer |

---

------